

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22 2017

Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study led by researchers at the Keck School of Medicine of USC.

That trend is problematic considering that African-Americans—the most at-risk population for multiple myeloma—have different genetics that can affect how this type of cancer progresses and what kind of targeted therapies are most effective, said Zarko Manojlovic, lead author of the study.

For example, in the study, multiple myeloma [patients](#) of European descent were six times more likely than their African peers to have mutations in the TP53 gene, a [tumor suppressor](#) that helps prevent cancer. African-Americans, on the other hand, experienced heightened mutations in BCL7A, a different [tumor suppressor gene](#).

"A cancer therapy that targets TP53 would not be as effective for African-Americans with multiple myeloma as it would be for a white population because doctors would be trying to fix the wrong mutated gene," said Manojlovic, assistant professor of research translational genomics at the Keck School of Medicine.

The study was published on Nov. 22 in *PLOS Genetics*. Researchers analyzed the genetic sequencing data of 718 multiple myeloma patients

and found that African-Americans had increased mutations in the [genes](#) BCL7A, BRWD3 and APTS2, while white people had more mutations in the genes TP53 and IRF4.

The study is the largest and most ethnically diverse genomics study of multiple myeloma to date, the researchers said.

The scientists genetically analyzed the ancestry for all patients and found that 127 patients were of African descent and 591 were of European descent.

"There are clearly molecular differences between African-American and Caucasian multiple myeloma cases, and it will be critical to pursue these observations to better improve clinical management of the disease for all patients," said John D. Carpten, senior author of the study and chair of the Department of Translational Genomics at the Keck School of Medicine.

Higher incidence rate and lower survival rates for African-Americans

Multiple myeloma is a cancer of plasma cells in the blood that causes tumor growths in bone marrow. About 30,280 people will be diagnosed with the cancer this year, and about half of them will survive longer than five years, according to the National Cancer Institute.

African-Americans are two times more likely than white people to die from multiple myeloma, the study stated.

"In the past decade, new treatments for the disease have spurred a remarkable improvement in survival for myeloma patients, but those benefits have disproportionately increased survival rates for Caucasian

patients," Carpten said. "African-American [multiple myeloma](#) patients have higher incidence rates and lower survival rates than their Caucasian peers despite this being a relatively easy-to-treat cancer.

"We in the [cancer](#) genomics community have a responsibility to ensure that our studies represent true population diversity so we can understand the role of ancestry and biology in health outcomes. The new candidate [myeloma](#) genes we identified in the African-American population may have been overlooked because of the lack of diversity in previous genomic efforts."

Provided by University of Southern California

Citation: One-size treatment for blood cancer probably doesn't fit all, researchers say (2017, November 22) retrieved 17 April 2024 from <https://medicalxpress.com/news/2017-11-one-size-treatment-blood-cancer-doesnt.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
